Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | AXL | P30530 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.37 |
| ▸ | NPC1 | O15118 | 3/20 | 0.37 |
| ▸ | PI4KA | P42356 | 3/20 | 0.37 |
| ▸ | PI4KB | Q9UBF8 | 3/20 | 0.37 |
| ▸ | SCN4A | P35499 | 2/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29594896 | 0.79 | RAB9A (0.41) | RAB9AMAPTHTTAXLGFER | |
| SCHEMBL799228 | 0.79 | RAB9A (0.41) | RAB9AMAPTHTTAXLGFER | |
| SCHEMBL2666929 | 0.78 | RAB9A (0.42) | RAB9AMAPTHTTAXLGFER | |
| SCHEMBL558903 | 0.75 | AXL (0.48) | RAB9AMAPTHTTAXLGFER | |
| SCHEMBL30526769 | 0.75 | GAA (0.48) | RAB9AMAPTHTTAXLGFER | |
| SCHEMBL30136461 | 0.75 | RAB9A (0.40) | RAB9AMAPTHTTAXLGFER | |
| SCHEMBL31109671 | 0.75 | RAB9A (0.48) | RAB9AMAPTHTTAXLGFER | |
| SCHEMBL113113 | 0.75 | RAB9A (0.40) | RAB9AMAPTHTTAXLGFER | |
| SCHEMBL5533108 | 0.75 | RAB9A (0.48) | RAB9AMAPTHTTAXLGFER | |
| SCHEMBL30858903 | 0.75 | AXL (0.48) | RAB9AMAPTHTTAXLGFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120214735-A1 | ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND MEDICINAL APPLICATIONS | ADVINUS THERAPEUTICS LIMITED (IN) | 2012-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214735-A1 | ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND MEDICINAL APPLICATIONS | GCK, GCKR, ALDOA | RAB9A 3085/4885MAPT 324/4885HTT 1526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.